% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lding:282465,
      author       = {S. Löding and U. Andersson and R. Kaaks$^*$ and M. B.
                      Schulze and V. Pala and I. Urbarova and P. Amiano and S. M.
                      Colorado-Yohar and M. Guevara and A. K. Heath and A. C.
                      Chatziioannou and M. Johansson and L. Nyberg and H. Antti
                      and B. Björkblom and B. Melin},
      title        = {{A}ltered plasma metabolite levels can be detected years
                      before a glioma diagnosis.},
      journal      = {JCI insight},
      volume       = {8},
      number       = {19},
      issn         = {2379-3708},
      address      = {Ann Arbor, Michigan},
      publisher    = {JCI Insight},
      reportid     = {DKFZ-2023-01780},
      pages        = {e171225},
      year         = {2023},
      note         = {2023 Oct 9;8(19):e171225},
      abstract     = {Genetic and metabolic changes in tissue and blood are
                      reported to occur several years before glioma diagnosis. As
                      gliomas are currently detected late, a liquid biopsy for
                      early detection could impact the quality of life and
                      prognosis of patients. Here, we present a nested
                      case-control study of 550 pre-diagnostic glioma cases and
                      550 healthy controls, from the Northern Sweden Health and
                      Disease study (NSHDS) and the European Prospective
                      Investigation into Cancer and Nutrition (EPIC) study. We
                      identified 93 significantly altered metabolites related to
                      glioma development up to eight years before diagnosis. Out
                      of these metabolites, a panel of 20 selected metabolites
                      showed strong disease correlation and consistent progression
                      pattern towards diagnosis in both the NSHDS and EPIC
                      cohorts, and separated favorably future cases from controls
                      independently of biological sex. The blood metabolite panel
                      also successfully separated both lower grade glioma and
                      glioblastoma cases from controls, up to eight years before
                      diagnosis in NSHDS (glioma AUC=0.85, P=3.1e-12; glioblastoma
                      AUC=0.85, P=6.3e-8), and up to two years before diagnosis in
                      EPIC (glioma AUC=0.81, P=0.005; glioblastoma AUC=0.89,
                      P=0.04). Pathway enrichment analysis detected metabolites
                      related to the TCA-cycle, Warburg effect, gluconeogenesis,
                      cysteine-, pyruvate- and tyrosine metabolism as the most
                      affected.},
      keywords     = {Brain cancer (Other) / Metabolism (Other) / Oncology
                      (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37651185},
      doi          = {10.1172/jci.insight.171225},
      url          = {https://inrepo02.dkfz.de/record/282465},
}